Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:19 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis
NCT04999020 · Alexion Pharmaceuticals, Inc. · PHASE2/PHASE3 · terminated · last registry update 2025-07-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision” | – | Registry record, Alexion Pharmaceuticals, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against C5 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-06-09Also stopped (withdrawn): University Hospital, Rouen, Eculizumab administration (NCT05702996)
- 2026-06-05Results posted on the registry: Alexion Pharmaceuticals, Inc., Ravulizumab (NCT06578949)
- 2026-06-01Results posted on the registry: Alexion Pharmaceuticals, Inc., Eculizumab (NCT05886244)
- 2026-05-19Phase 3 first posted: Alexion Pharmaceuticals, Inc., Ravulizumab (NCT07596784)
- 2026-04-29Phase 3 first posted: Alexion Pharmaceuticals, Inc., Ravulizumab (NCT07557420)
- 2026-04-14Results posted on the registry: Astellas Pharma Global Development, Inc., avacincaptad pegol (NCT05536297)
- 2026-03-27Results posted on the registry: UCB Biopharma SRL, Zilucoplan (NCT06471361)
- 2026-03-12Results posted on the registry: Astellas Pharma Global Development, Inc., avacincaptad pegol + Sham (NCT03364153)
- 2026-03-02Also stopped (withdrawn): Hoffmann-La Roche, Crovalimab + Placebo (NCT07172022)
- 2026-02-19Phase 3 first posted: Tianjin Medical University General Hospital, Eculizumab administration + High-dose corticosteroid pulse therapy (NCT07420296)
- 2026-01-22Results posted on the registry: Alexion Pharmaceuticals, Inc., Ravulizumab + Placebo (NCT04564339)
- 2026-01-22Also stopped (terminated): Alexion Pharmaceuticals, Inc., Ravulizumab + Placebo (NCT04564339)
- 2026-01-12Results posted on the registry: Alexion Pharmaceuticals, Inc., Ravulizumab (NCT04557735)
- 2026-01-06Results posted on the registry: UCB Biopharma SRL, Zilucoplan (NCT06511076)
- 2025-12-08Results posted on the registry: Alexion Pharmaceuticals, Inc., Eculizumab (NCT05876351)
- 2025-11-20Also stopped (withdrawn): Assistance Publique - Hôpitaux de Paris, Eculizumab (NCT02113891)
- 2025-11-10Results posted on the registry: Hoffmann-La Roche, Crovalimab + Eculizumab (NCT04434092)
- 2025-11-04Also stopped (terminated): InflaRx GmbH, vilobelimab + Placebo (NCT05964413)
- 2025-10-14Phase 3 first posted: Miriam Freimer, Zilucoplan® (NCT07215949)
- 2025-09-17Phase 3 first posted: Nanjing Chia-tai Tianqing Pharmaceutical, NTQ5082 capsules 200 mg + Eculizumab Injection (NCT07177859)
- 2025-09-10Also stopped (withdrawn): Tianjin Medical University General Hospital, Complement protein C5 inhibitor + IVMP (NCT06673394)
- 2025-09-04Phase 3 first posted: Regeneron Pharmaceuticals, Pozelimab + Cemdisiran (NCT07154745)
- 2025-06-25Results posted on the registry: Regeneron Pharmaceuticals, Pozelimab + Cemdisiran (NCT04888507)
- 2025-06-17Phase 3 first posted: Alexion Pharmaceuticals, Inc., Ravulizumab (NCT07024563)
- 2025-06-05Also stopped (terminated): AKARI Therapeutics, nomacopan (rVA576) (NCT04784455)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision